Victor W. van Beusechem
Technik-/Wissenschafts-/F&E-Leiter bei ORCA Therapeutics BV
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kees Groen | M | 63 |
ORCA Therapeutics BV
 ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
| Mark R.L. Krul | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
| Jan Hendrik Egberts | M | 65 |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
| Ramon Alemany | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
| Wenliang Dong | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Onno van de Stolpe | M | 64 |
Introgene BV
| 1 Jahre |
| Abraham Bout | M | - |
Janssen Vaccines & Prevention BV
 Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | 14 Jahre |
| Menzo Havenga | M | - |
Introgene BV
| 7 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Niederlande | 8 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Victor W. van Beusechem
- Persönliches Netzwerk